Pulmonary Clinical Trials

5 recruiting

Pulmonary Trials at a Glance

999 actively recruiting trials for pulmonary are listed on ClinicalTrialsFinder across 6 cities in 87 countries. The largest study group is Not Applicable with 297 trials, with the heaviest enrollment activity in Beijing, Philadelphia, and Boston. Lead sponsors running pulmonary studies include China-Japan Friendship Hospital, AstraZeneca, and Peking Union Medical College Hospital.

Treatments under study

About Pulmonary Clinical Trials

Looking for clinical trials for Pulmonary? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Pulmonary trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Pulmonary clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 999 trials

Recruiting
Phase 2Phase 3

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Advanced Extrapulmonary Neuroendocrine CarcinomaMetastatic Extrapulmonary Neuroendocrine CarcinomaRecurrent Extrapulmonary Neuroendocrine Carcinoma+1 more
National Cancer Institute (NCI)189 enrolled244 locationsNCT05058651
Recruiting

DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study

Pleuropulmonary BlastomaCystic NephromaNasal Chondromesenchymal Hamartoma+2 more
National Cancer Institute (NCI)1,500 enrolled2 locationsNCT01247597
Recruiting
Phase 3

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

Progressive Pulmonary FibrosisIdiopathic Pulmonary Fibrosis
Boehringer Ingelheim1,700 enrolled371 locationsNCT06238622
Recruiting
Phase 2

Spironolactone for Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension
National Institutes of Health Clinical Center (CC)70 enrolled1 locationNCT01712620
Recruiting
Phase 2

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim71 enrolled47 locationsNCT07036523
Recruiting
Phase 2

A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood

Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim20 enrolled3 locationsNCT06241560
Recruiting
Not Applicable

Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD

Chronic Obstructive Pulmonary DiseaseCOPD
Nuvaira, Inc.200 enrolled10 locationsNCT07051707
Recruiting

Fungal Infection Susceptibility

Cryptococcal MeningitisCryptococcosisCryptococcal Infection+2 more
National Institute of Allergy and Infectious Diseases (NIAID)800 enrolled1 locationNCT00001352
Recruiting
Not Applicable

Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions

Genetic TestingPulmonary Arterial HypertensionHeart Defects, Congenital
Universitaire Ziekenhuizen KU Leuven21 enrolled1 locationNCT02691689
Recruiting
Phase 3

Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy

Pulmonary Embolism
NYU Langone Health500 enrolled40 locationsNCT05591118
Recruiting
Not Applicable

Telerehabilitation in Patients With Elevated Pulmonary Artery Pressure

Elevated Pulmonary Artery Pressure
Marmara University12 enrolled1 locationNCT07535398
Recruiting
Phase 3

A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

Interstitial Lung DiseasesFamilial Pulmonary FibrosisInterstitial Lung Abnormalities
Boehringer Ingelheim80 enrolled56 locationsNCT07201922
Recruiting
Phase 2

Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary Tuberculosis

Drug Susceptible Pulmonary Tuberculosis
Gates Medical Research Institute150 enrolled13 locationsNCT07525427
Recruiting
Phase 2

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Pulmonary Hypertension
Pfizer36 enrolled44 locationsNCT07073820
Recruiting
Phase 2

Effects of IVIG for BPD in Preterm Infant Born at 28 Weeks and Below

Bronchopulmonary Dysplasia
International Peace Maternity and Child Health Hospital29 enrolled1 locationNCT07561125
Recruiting

Validation and Clinical Utility of the Lung Sliding Index (LSI) for Differentiating Pulmonary Diseases

PneumothoraxCOPDPneumonia+4 more
Assiut University700 enrolled1 locationNCT06983366
Recruiting

Can Ultrasound-Guided Fascial Plane Blocks Reduce Postoperative Pulmonary Complications After Major Abdominal Surgery?

Postoperative Pain ManagementAbdominal SurgeriesPostoperative Pulmonary Complications (PPCs)
Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital500 enrolled1 locationNCT07394816
Recruiting
Phase 1

Study of Intravenous ZMA001 in Healthy Subjects

Pulmonary Arterial Hypertension PAH
National Heart, Lung, and Blood Institute (NHLBI)96 enrolled1 locationNCT05967299
Recruiting
Phase 2

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

Progressive Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)
Avalyn Pharma Inc.340 enrolled52 locationsNCT06951217
Recruiting
Not Applicable

Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis
Assiut University30 enrolled2 locationsNCT05842681